On Monday, Celldex Therapeutics Inc (NASDAQ: CLDX) opened higher 6.52% from the last session, before settling in for the closing price of $25.6. Price fluctuations for CLDX have ranged from $14.40 to $30.50 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 6.91%. Company’s average yearly earnings per share was noted -49.37% at the time writing. With a float of $64.55 million, this company’s outstanding shares have now reached $66.45 million.
Celldex Therapeutics Inc (CLDX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Celldex Therapeutics Inc is 2.82%, while institutional ownership is 107.35%. The most recent insider transaction that took place on Dec 04 ’25, was worth 121,210. In this transaction SVP & GENERAL COUNSEL of this company sold 4,166 shares at a rate of $29.09, taking the stock ownership to the 30,796 shares. Before that another transaction happened on Dec 04 ’25, when Company’s Officer proposed sale 4,166 for $29.10, making the entire transaction worth $121,210.
Celldex Therapeutics Inc (CLDX) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.71 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.71) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -49.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -23.43% during the next five years compared to 6.91% growth over the previous five years of trading.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Check out the current performance indicators for Celldex Therapeutics Inc (CLDX). In the past quarter, the stock posted a quick ratio of 13.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 696.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.38, a number that is poised to hit -1.00 in the next quarter and is forecasted to reach -4.45 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
The latest stats from [Celldex Therapeutics Inc, CLDX] show that its last 5-days average volume of 0.81 million was inferior to 0.99 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 26.24%.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 70.03%, which indicates a significant increase from 41.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.35 in the past 14 days, which was higher than the 1.27 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.29, while its 200-day Moving Average is $22.68. Now, the first resistance to watch is $28.33. This is followed by the second major resistance level at $29.39. The third major resistance level sits at $30.87. If the price goes on to break the first support level at $25.80, it is likely to go to the next support level at $24.32. The third support level lies at $23.26 if the price breaches the second support level.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
There are currently 66,449K shares outstanding in the company with a market cap of 1.81 billion. Presently, the company’s annual sales total 7,020 K according to its annual income of -157,860 K. Last quarter, the company’s sales amounted to 730 K and its income totaled -56,600 K.
